The Modification of Diet in Renal Disease Study (MDRD) did not address the end point of deterioration of renal function, such as ESRD, and there was a difference in the proportion of angiotensin-converting-enzyme (ACE) inhibitor use between the lower blood pressure group and the usual care group of patients, which limited the observations of the results [5]. This evidence concerns the gene ACE and kidney disorder.